FIGURE 1.

The progression‐free survival of all 71 patients treated with atezolizumab + bevacizumab analyzed using Kaplan–Meier curve.

The progression‐free survival of all 71 patients treated with atezolizumab + bevacizumab analyzed using Kaplan–Meier curve.